双成药业(002693) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥78,836,391.40, a decrease of 17.68% compared to ¥95,765,554.61 in the same period last year[8]. - The net profit attributable to shareholders was -¥8,882,719.71, representing a decline of 157.87% from -¥3,444,618.98 year-on-year[8]. - The total comprehensive income for Q1 2019 was -¥12,701,960.32, compared to -¥6,401,024.26 in the previous year, showing a worsening financial position[39]. - The company reported a net loss of CNY 188,195,999.30 for Q1 2019, compared to a net loss of CNY 177,939,478.76 in Q1 2018[35]. - The total profit for Q1 2019 was -¥11,717,827.70, compared to -¥6,401,024.26 in the previous year, highlighting ongoing financial difficulties[39]. Cash Flow - The net cash flow from operating activities was ¥17,760,557.48, down 13.18% from ¥20,457,146.29 in the previous year[8]. - Cash received from operating activities increased by 787.46% year-on-year, mainly due to a sales promotion deposit received by a subsidiary[18]. - The net cash flow from investment activities was 86,206,615.55 CNY, an increase of 172.5% compared to the previous period's 31,636,693.77 CNY[44]. - The net cash flow from financing activities was -124,189,448.45 CNY, worsening from -60,694,590.79 CNY in the previous period[44]. Assets and Liabilities - The total assets at the end of the reporting period were ¥985,258,510.81, a decrease of 12.05% from ¥1,120,245,836.67 at the end of the previous year[8]. - The company's total liabilities decreased to CNY 328,360,132.04 from CNY 450,558,753.74, a reduction of 27.1%[30]. - The total assets of the company as of March 31, 2019, were CNY 691,446,739.30, down from CNY 843,742,894.77, a decline of 18%[33]. - The cash and cash equivalents decreased to CNY 43,478,363.18 from CNY 65,990,293.61, a drop of 34.1%[32]. Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 33,312[11]. - The largest shareholder, Hainan Shuangcheng Investment Co., Ltd., held 34.45% of the shares, totaling 139,516,546 shares[11]. Expenses - Total operating costs for Q1 2019 were CNY 92,824,160.52, down from CNY 103,379,546.44 in Q1 2018, reflecting a reduction of 10.2%[37]. - Research and development expenses increased significantly to CNY 8,785,990.06, up 166.5% from CNY 3,298,713.53 in the previous year[37]. - The company incurred sales expenses of ¥33,451,237.26, down from ¥41,991,529.94 in the previous period, reflecting cost-cutting measures[41]. Financial Adjustments - The company implemented new financial instrument standards starting January 1, 2019, adjusting liquid assets from "other current assets" to "trading financial assets" with an amount of ¥120,478,000[51]. - The company's trading financial assets were newly recognized at ¥120,478,000.00, reflecting a significant adjustment in asset classification[55]. Other Financial Metrics - The company's weighted average return on equity was -1.72%, a decline of 1.14% compared to -0.58% in the same period last year[8]. - Interest income increased by 128.25% year-on-year, mainly due to an increase in interest income from time deposits during the reporting period[16]. - Investment income surged by 687.85% compared to the same period last year, primarily due to increased financial management income during the reporting period[16].